Gilead Sciences (NASDAQ:GILD) Now Covered by Barclays

Barclays assumed coverage on shares of Gilead Sciences (NASDAQ:GILD) in a report issued on Friday morning, Marketbeat Ratings reports. The brokerage issued an equal weight rating and a $155.00 target price on the biopharmaceutical company’s stock.

GILD has been the topic of several other reports. BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, January 26th. TD Cowen raised their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Sanford C. Bernstein reissued an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a research report on Wednesday, February 11th. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Finally, Needham & Company LLC raised their price objective on Gilead Sciences from $140.00 to $170.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $155.44.

Gilead Sciences Trading Up 0.2%

Shares of Gilead Sciences stock opened at $151.40 on Friday. Gilead Sciences has a 12-month low of $93.37 and a 12-month high of $157.29. The stock has a market cap of $187.84 billion, a P/E ratio of 22.36, a P/E/G ratio of 2.01 and a beta of 0.36. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. The business’s 50 day moving average is $133.47 and its 200-day moving average is $123.63.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s revenue was up 4.7% on a year-over-year basis. During the same period last year, the business earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio is presently 46.68%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the transaction, the director directly owned 8,920 shares of the company’s stock, valued at $1,115,713.60. This represents a 35.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer owned 566,698 shares in the company, valued at $76,504,230. The trade was a 16.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 319,891 shares of company stock worth $45,091,556 over the last three months. Company insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. Brighton Jones LLC increased its holdings in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC bought a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $215,000. Sivia Capital Partners LLC grew its position in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 602 shares in the last quarter. Cookson Peirce & Co. Inc. bought a new position in Gilead Sciences during the 2nd quarter worth $319,000. Finally, Exencial Wealth Advisors LLC increased its stake in Gilead Sciences by 12.7% during the 2nd quarter. Exencial Wealth Advisors LLC now owns 3,470 shares of the biopharmaceutical company’s stock worth $385,000 after acquiring an additional 390 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 earnings beat and firm guidance: Gilead reported $1.86 EPS vs. $1.83 est. and $7.93B revenue (above estimates) and set FY‑2026 EPS guidance of $8.45–$8.85 — a catalyst for re-rating. Analyst Reactions Post‑Earnings
• Positive Sentiment: Argus raised its price target to $165 and kept a Buy rating, adding analyst-driven upside (~mid-single digits vs. current levels). Argus PT Raise
• Positive Sentiment: Mizuho lifted its target to $170 and kept an Outperform rating, supporting a higher consensus valuation and momentum for buy‑side flows. Mizuho PT Raise
• Neutral Sentiment: Barclays initiated coverage with an Equal‑Weight rating and $155 target — neither a strong buy nor a sell signal, but it provides fresh institutional coverage. Barclays Coverage
• Neutral Sentiment: Broader analyst and media coverage (Zacks, Yahoo, Benzinga retrospectives) is keeping GILD in focus for retail/institutional investors; these pieces inform positioning but are mixed in directional impact. Zacks Coverage
• Neutral Sentiment: Short‑interest data in the feed looks anomalous/zeroed out and provides no clear sell pressure signal at present (data likely noisy).
• Negative Sentiment: Insider selling: CFO Andrew Dickinson sold 3,000 shares (~$154.43 avg price) — a small amount but negative for sentiment when combined with other insider moves. CFO Form 4
• Negative Sentiment: Material insider sale: Johanna Mercier sold 28,000 shares (~$154.44 avg), an ~18.9% reduction in her holding — a larger ticket that can weigh on investor confidence. Mercier Form 4
• Negative Sentiment: “Time to take profits” / rating downgrade commentary is circulating, which can trigger short‑term selling from momentum traders. Seeking Alpha Take‑Profits Piece

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.